Adalimumab +MTX	MTX	Clinical remissions	16895	17026	Approximately twice as many patients in the ADA+MTX group achieved remission or LDA compared with methotrexate monotherapy (p<0.001
Adalimumab +MTX	MTX	ACR20 improvements 	1219	1324	Combination therapy was statistically superior to methotrexate in obtaining higher ACR20/50/70 responses,
Adalimumab +MTX	MTX	Clinical remissions	1219	1350	Combination therapy was statistically superior to methotrexate in obtaining higher ACR20/50/70 responses, more clinical remissions,
Adalimumab +MTX	MTX	Stable low disease activity	15537	15769	Among patients treated with ADA+MTX who completed 26 weeks and were eligible for re-randomisation, 44% (207/466) achieved the stable LDA target, compared with 24% (112/460) in the methotrexate monotherapy group (p<0.001; figure 2A).
Adalimumab +MTX	MTX	ACR20 improvements 	1219	1477	Combination therapy was statistically superior to methotrexate in obtaining higher ACR20/50/70 responses, more clinical remissions, greater mean reductions in DAS28(CRP), no radiographic progression, and normal functional status at week 26 (p<0.001 for all).
Adalimumab +MTX	MTX	DAS28 improvement 	1219	1477	Combination therapy was statistically superior to methotrexate in obtaining higher ACR20/50/70 responses, more clinical remissions, greater mean reductions in DAS28(CRP), no radiographic progression, and normal functional status at week 26 (p<0.001 for all).
Adalimumab +MTX	MTX	Stable low disease activity	15537	15757	Among patients treated with ADA+MTX who completed 26 weeks and were eligible for re-randomisation, 44% (207/466) achieved the stable LDA target, compared with 24% (112/460) in the methotrexate monotherapy group (p<0.001;
Adalimumab +MTX	MTX	Achieving normal functional status 	1219	1477	Combination therapy was statistically superior to methotrexate in obtaining higher ACR20/50/70 responses, more clinical remissions, greater mean reductions in DAS28(CRP), no radiographic progression, and normal functional status at week 26 (p<0.001 for all).
Adalimumab +MTX	MTX	Stop of radiographic progression	1219	1477	Combination therapy was statistically superior to methotrexate in obtaining higher ACR20/50/70 responses, more clinical remissions, greater mean reductions in DAS28(CRP), no radiographic progression, and normal functional status at week 26 (p<0.001 for all).
